NASDAQ · QTTB
Q32 Bio Inc.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
Loading market information…
NASDAQ · MIRA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MIRA Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.34% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
MIRA Pharmaceuticals, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow MIRA Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $11.16M |
| Q3 2024 | Nov 12, 2024 | -$0.14+22.22% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$1.07-$0.02 (-1.83%)
Talphera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.85% below the high.
$1.30+$0.04 (+3.17%)
Myomo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.22% below the high.
$4.59+$0.25 (+5.76%)
Precision Optics Corporation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.37% below the high.
$1.43-$0.02 (-1.38%)
NanoViricides, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.87% below the high.
$0.32-$0.00 (-0.54%)
Milestone Scientific Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.69% below the high.
$0.20-$0.04 (-16.55%)
IGC Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.81% below the high.
